

(10) International Publication Number
WO 2016/036937 A1(43) International Publication Date
10 March 2016 (10.03.2016)

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2015/048316

(22) International Filing Date:

3 September 2015 (03.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


62/046,682 5 September 2014 (05.09.2014) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).(72) Inventors: GAUDET, Francois; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). ATTAR, Ri-
cardo; 1400 McKean Road, Spring House, Pennsylvania
19477 (US). HARMAN, Benjamin C.; 1400 McKean
Road, Spring House, Pennsylvania 19477 (US). LI, Ying-
zhe; 1400 McKean Road, Spring House, Pennsylvania
19477 (US). LUO, Jinquan; 1400 McKean Road, Spring
House, Pennsylvania 19477 (US). MCDAID, Ronan;
1400 McKean Road, Spring House, Pennsylvania 19477
(US). POMERANTZ, Steven C.; 1400 McKean Road,Spring House, Pennsylvania 19477 (US). TAM, Susan H.;
1400 McKean Road, Spring House, Pennsylvania 19477
(US). TEPLYAKOV, Alexey; 1400 McKean Road, Spring
House, Pennsylvania 19477 (US). WHEELER, John;
1400 McKean Road, Spring House, Pennsylvania 19477
(US). WU, Sheng-Jiun; 1400 McKean Road, Spring
House, Pennsylvania 19477 (US). NEMETH, Jennifer F.;
1400 McKean Road, Spring House, Pennsylvania 19477
(US).(74) Agents: PLANTZ, Bernard F. et al.; JOHNSON &
JOHNSON, One Johnson & Johnson Plaza, New Brun-
swick, New Jersey 08933 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: CD123 BINDING AGENTS AND USES THEREOF

Figure 1.

Comments for pDisplay™:
§325 nucleotides

(57) Abstract: Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))